Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peg-Neutropine
- Development stage
- Unknown
- Lead developer
- Gema Biotech
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Peg-Neutropine is a biosimilar of pegfilgrastim developed by Gema Biotech for the prevention of febrile neutropenia in patients receiving myelosuppressive chemotherapy. It is a pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF). By binding to the G-CSF receptor, it stimulates the production, maturation, and activation of neutrophils, thereby reducing the duration and severity of neutropenia. The pegylation increases the molecular size and reduces renal clearance, allowing for a single 6 mg subcutaneous dose per chemotherapy cycle. It was the first pegfilgrastim biosimilar approved in Latin America, specifically in Argentina, following clinical trials demonstrating equivalence to the reference product.
- Brand names
- Peg-Neutropine
- Other names
- pegfilgrastim
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on Peg-Neutropine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peg-Neutropine.